

## Meeting

### **4<sup>th</sup> Milan “Me(e)t immune” Conference**

#### ***How Metabolism Meets the Immune System in Human Malignancies***

Milan, May 18-19th 2026

*Sarà richiesto il patrocinio a:*

*AIOM, SIC (tbd), SIF, AIRC, Società Italiana di Immunologia (tbd)*

*IFOM, IRCCS Istituto Nazionale Tumori, Università degli Studi Milano, EURAMA Precision  
Oncology*

## [ Preliminary Program ]

**Monday, May 18<sup>th</sup>**

11.30 Registration and Light lunch

12.30 Meeting Introduction  
Maria Teresa Montella, Paolo Corradini,

### **SESSION 1**

#### **Evolution in cancer therapy: from present to future**

Chairman: Filippo de Braud, Claudio Vernieri

13.00 The transformative journey of cancer treatment: towards a global cure?  
Filippo de Braud

13.30 Cancer metabolism as a targetable hallmark of cancer: reaching the last mile  
Claudio Vernieri

14.00 How immunology meets the other hallmark of cancer: a lesson from basic research  
Alberto Bardelli

14.30 Discussion

### **SESSION 2**

#### **Implement multiomics biological analyses and AI methods to study cancer immunometabolism**

Chairman: Giancarlo Pruneri, Sabina Sangaletti

15.00 Tumor transcriptomics to study cancer metabolism and immunology  
Massimiliano Pagani

15.20 Bulk and single cell proteomics and metabolomics to study cancer metabolism and immunology  
Mattia Rediti

15:40 Radiomics and digital pathology to study cancer metabolism: challenges and opportunities  
Arsela Prelaj

16.00 Discussion

16.30 *Coffee break*

### **SESSION 3**

#### **Interaction between metabolic interventions and specific standard treatments**

Chairman: Massimo Di Nicola, Marilena Iorio

17.00 How fasting cooperates with hormone therapies  $\pm$  CDK 4/6i for breast cancer  
Alessio Nencioni

17.20 Metabolism and PI3K/AKT/mTORC1 axis inhibitors in cancer therapy  
Claudio Vernieri

17.40 How metabolic treatments and microbiota impact the efficacy of immune checkpoint inhibitors  
Francesco Schettini

18.00 Potential impact of metabolic interventions on ADC and bispecific antibody efficacy

Giuseppe Curigliano

18.20 Discussion

18.30 Adjourn

NO CME SESSION

Lecture during dinner: Antonio Albanese (tbd)

Osteria del Treno

**Tuesday, May 19<sup>th</sup>**

**SESSION 4**

**Impact of nutrition and lifestyle interventions on cancer treatment efficacy and safety**

Chairman: Patrizia Pasanisi, Tiziana Triulzi

9.00 How nutrition impacts on the efficacy and tolerability of anticancer treatments  
Riccardo Caccialanza

9.30 Physical exercise and clinical outcomes in cancer: an emerging connection  
Alessandra Raimondi

10.00 Impact of body composition on cancer treatment efficacy and tolerability  
Patrizia Pasanisi

10.30 Role of anti-obesity and antidiabetic drugs on cancer therapy efficacy  
Paolo Fiorina

11.00 Discussion

**SESSION 5**

**Impact of Scientific Institutions and patients advocacy in cancer metabolism research**

Chairman: Filippo de Braud, Claudio Vernieri

11.20 Role of patient associations in supporting clinical research on cancer metabolism  
Rosanna D'Antona (Europa Donna)

11.40 Role of patient advocates in promoting clinical research on cancer metabolism  
Laura Marziali

12.00 Discussion

12.30 Lunch

**SESSION 6**

**Calorie restriction in cancer therapy**

Chairman: Claudio Vernieri, Filippo de Braud

13.30 Past  
Andreas Michalsen

13.50 Present  
Christine Desmedt

14.10 Future

Francesca Ligorio

14.30 Discussion

15.00 **LECTURE**

Pharmacological treatments and systemic metabolism in cancer patients

Romano Danesi

## **SESSION 7**

### **Role of Institution in supporting research on cancer metabolism**

Chairman:.....

15.30 Role of AIRC in supporting academic and innovative research on cancer metabolism  
Anna Mondino

16.00 How regulatory agencies (EMA/AIFA) can support innovative research on cancer metabolism  
Paolo Foggi

16.30 How scientific associations (AIOM) can sustain academic research on cancer metabolism  
Massimo Di Maio

17.00 Discussion

17.20 Take home messages  
Filippo de Braud and Claudio Vernieri

17.30 Adjourn

## **[Objectives]**

Scientific evidence shows that the modulation of systemic and tumor metabolism influences crucial properties of human malignancies, such as cancer cell growth, invasion, immunoregulation, metastasis and response to standard pharmacologic treatments. In detail, modulating systemic and intratumor metabolism could improve the efficacy and tolerability of cytotoxic chemotherapy, immune checkpoint inhibitors, antibody drug-conjugates, bispecific antibodies, CDK4/6 inhibitors, PI3K/AKT/mTORC inhibitors, and rationale for their combinations.

The objective of this Conference, the fourth of a series of annual congresses on this topic, is to bring together national and international scientists and oncologists who are expert in the fields of cancer metabolism, immunology and innovative anticancer drugs, with the aim of sharing and discussing the most recent advances and future clinical perspectives of metabolic approaches. The Speakers will focus on experimental therapeutic strategies that impact on cancer cell biology and on the activation status of the immune system through the modulation of host and tumor metabolism. The Speakers will also focus on the effects of available or experimental pharmacologic therapies, such as novel PI3K or AKT inhibitors, on the metabolism of the host, and they will discuss how to properly prevent or manage metabolic toxicities of these treatments to improve their antitumor activity.

## **[Addressed to]**

Medical oncologists, clinical nutritionists, pathologists, radiologists, radiation oncologists, palliative care specialists. Pharmacists. Biologists, chemists (except session 3).

## [Course Director]

### **Filippo de Braud**

Dipartimento di Oncologia  
S.C. Oncologia Medica 1  
Fondazione IRCCS Istituto Nazionale Tumori  
Milano

Dipartimento di Oncologia ed Oncologia-Ematologia  
Università degli studi di Milano  
Milano

## [Scientific Committee]

### **Claudio Vernieri**

Dipartimento di Oncologia  
S.C. Oncologia Medica 1  
Fondazione IRCCS Istituto Nazionale Tumori  
Milano

Dipartimento di Oncologia ed Oncologia-Ematologia  
Università degli studi di Milano  
Milano

Metabolic Reprogramming in Solid Tumors Unit  
IFOM, Istituto Fondazione di Oncologia Molecolare ETS  
Milano

## [Speakers]

### **Alberto Bardelli**

Dip. di Scienze Oncologiche Oncologia Molecolare  
IRCC Istituto per la Ricerca e la Cura del Cancro – Candiolo (TO)  
Università degli Studi di Torino  
IFOM ETS - The AIRC Institute of Molecular Oncology  
Milano

### **Riccardo Caccialanza**

S.C. Dietetica e Nutrizione Clinica  
Fondazione IRCCS Policlinico San Matteo  
Pavia

### **Paolo Corradini**

Direzione Scientifica  
Divisione Ematologia  
Fondazione IRCCS Istituto Nazionale Tumori  
Università degli Studi  
Milano

### **Giuseppe Curigliano**

Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative  
IEO - Istituto Europeo di Oncologia IRCCS  
Dipartimento di Oncologia ed Emato-Oncologia  
Università degli Studi  
Milano

**Romano Danesi**

Dipartimento di Oncologia ed Emato-Oncologia  
Università degli Studi "La Statale"  
Milano

**Filippo Guglielmo de Braud**

S.C. Oncologia Medica 1  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Dipartimento di Oncologia Medica  
Università degli Studi  
Milano

**Christine Desmedt**

Laboratory for Translational Breast Cancer Research  
Department of Oncology KU Leuven  
Leuven

**Massimo Di Nicola**

S.S. Immunoterapia clinica dei Tumori e terapie Innovative, Dipartimento di Oncologia ed Ematologia  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Milano

**Rosanna Fidanzia D'Antona**

Europa Donna  
Milano

**Paolo Fiorina**

Dipartimento di Scienze Biomediche e Cliniche "L. Sacco"  
Università degli Studi di Milano  
Milano

**Paolo Foggi**

Settore Innovazione e Strategia del Farmaco  
AIFA - Agenzia Italiana del Farmaco  
Roma

**Marilena Iorio**

Oncologia Sperimentale  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Milano

**Francesca Ligorio**

Dipartimento di Oncologia Medica  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Milano

**Andreas Michalsen**

Klinische Naturheilkunde  
Immanuel Albertinen Diakonie Charité – Universitätsmedizin Berlin  
Berlin

**Maria Teresa Montella**

Direzione Generale  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Milano

**Alessio Nencioni**

Ospedale Policlinico San Martino IRCCS  
Genova

**Massimiliano Pagani**

Biologia Molecolare  
Università degli Studi di Milano  
Milano

**Patrizia Pasanisi**

SSD Ricerca Nutrizionale e Metabolomica  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Milano

**Arsela Prelaj**

S.C. Oncologia Medica 1  
Fondazione IRCCS Istituto Nazionale Tumori  
Milano

**Giancarlo Pruneri**

S.C. Anatomia Patologica 2  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Milano

**Alessandra Raimondi**

S.S. Oncologia Gastroenterologica  
Fondazione IRCCS Istituto Nazionale Tumori  
Milano

**Mattia Rediti**

Metabolic Reprogramming in Solid Tumors  
IFOM Istituto Fondazione di Oncologia Molecolare  
Milano

**Sabina Sangaletti**

Oncologia Sperimentale  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Milano

**Francesco Schettini**

Translational genomics and targeted therapies in solid tumours  
Hospital Clínic of Barcelona  
Barcelona

**Tiziana Triulzi**

Dipartimento Oncologia Sperimentale  
Fondazione IRCCS Istituto Nazionale dei tumori  
Milano

**Claudio Vernieri**

Dipartimento di Oncologia  
S.C. Oncologia Medica 1  
Fondazione IRCCS Istituto Nazionale Tumori  
Milano

**[CME]**

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (.....): ..... CME credits.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialization and highly specialized activity. Rare disease.

The credit certification for the webinar is subject to:

- Professions/specializations should correspond to those which have been accredited for CME;
- attendance at the 90% of the meeting;
- the completion of the Meeting evaluation online form;
- completion of the final test (at least 75% of correct answers). 1 attempt admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

**[Meeting venue]**

Aula Magna  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Milano

**[Organizer]**

**ACCADEMIA NAZIONALE DI MEDICINA**

Direttore Generale: Stefania Ledda  
Via Martin Piaggio, 17/6  
16122 Genova

**[Information]**

[www.fad.accmed.org](http://www.fad.accmed.org)

Ph: 010 83794239

Mob: 3357112604

E-mail: [segreteriaacorsi@accmed.org](mailto:segreteriaacorsi@accmed.org)

**[Logistics and technological services]**

**Forum Service**

Via Martin Piaggio 17/8  
16122 Genova